Literature DB >> 16709521

Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.

Winnie W Cheung1, Gloria Y Hwang, Eric Tse, Yok-Lam Kwong.   

Abstract

A 58-year-old man with warm-antibody-mediated autoimmune hemolytic anemia (AIHA) refractory to prednisolone, azathioprine, splenectomy, rituximab and combination chemotherapy, and with unacceptably high transfusion requirement, was treated with alemtuzumab. After a cumulative dose of 883 mg of alemtuzumab, the AIHA remitted completely, with normalization of hemoglobin and transfusion-independence. The major side effect was reactivation of cytomegalovirus, which was controlled with intravenous and oral ganciclovir. This case showed that alemtuzumab might be of use in therapy-refractory AIHA.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16709521

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  12 in total

Review 1.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).

Authors:  Saverio Ladogana; Matteo Maruzzi; Piera Samperi; Annalisa Condorelli; Maddalena Casale; Paola Giordano; Lucia D Notarangelo; Piero Farruggia; Fiorina Giona; Agostino Nocerino; Silvia Fasoli; Maria L Casciana; Maurizio Miano; Fabio Tucci; Tommaso Casini; Paola Saracco; Wilma Barcellini; Alberto Zanella; Silverio Perrotta; Giovanna Russo
Journal:  Blood Transfus       Date:  2018-04-13       Impact factor: 3.443

Review 3.  The immunological function of CD52 and its targeting in organ transplantation.

Authors:  Yang Zhao; Huiting Su; Xiaofei Shen; Junfeng Du; Xiaodong Zhang; Yong Zhao
Journal:  Inflamm Res       Date:  2017-03-10       Impact factor: 4.575

Review 4.  Treatment of autoimmune hemolytic anemias.

Authors:  Alberto Zanella; Wilma Barcellini
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

5.  Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.

Authors:  David Chu; Michelle Stevens; Douglas Edward Gladstone
Journal:  Rheumatol Int       Date:  2007-04-19       Impact factor: 2.631

6.  Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.

Authors:  Sanjay R Mohan; Michael J Clemente; Manuel Afable; Heather N Cazzolli; Nelli Bejanyan; Marcin W Wlodarski; Alan E Lichtin; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

7.  Disease-modifying treatments for primary autoimmune haemolytic anaemia.

Authors:  Anthony Pak-Yin Liu; Daniel Kl Cheuk
Journal:  Cochrane Database Syst Rev       Date:  2021-03-26

8.  Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection: a case report and review of literature.

Authors:  Robert J Basseri; Michael T Schmidt; Benjamin Basseri
Journal:  Clin J Gastroenterol       Date:  2010-08-06

9.  Alemtuzumab induction therapy in solid organ transplantation.

Authors:  Peter J Friend
Journal:  Transplant Res       Date:  2013-11-20

10.  Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: a case report.

Authors:  Chiara Beretta; Veronica Leoni; Mario Renato Rossi; Momcilo Jankovic; Nicolo Patroniti; Giuseppe Foti; Ettore Biagi
Journal:  J Med Case Rep       Date:  2009-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.